According to GlobalData’s medical device pipeline database, ten HER2 Amplification Tests devices are in various stages of development globally. GlobalData’s report HER2 Amplification Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

All ten devices of this category are in active stage of development. There are three products in the early stages of development, and the remaining seven are in the late stages of development.

In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Human epidermal growth factor receptor 2 (HER2) tests, using biopsied tissue, typically breast tissue, are carried out to detect over-expression of the HER2 protein, or additional copies HER2/neu gene encoding for the protein; the outcome of which may guide therapies to treat certain breast cancers, along with some ovarian cancers uterine cancers, stomach cancers, and lung cancers. There are two main types of HER2 amplification tests: immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). IHC is a staining test that looks for the HER2 protein on the surface of cells. FISH is a genetic test that looks for extra copies of the HER2 gene. HER Tests includes Immunohistochemistry (IHC) Tests, In Situ Hybridisation (ISH) Tests, and Comparative genomic Hybridisation (aCGH) Tests.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed HER2 Amplification Tests pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of HER2 Amplification Tests devices. Overall, most of these HER2 Amplification Tests pipeline devices are being developed by private entities.

Key players involved in the active development of HER2 Amplification Tests include Daiichi Sankyo, GeneCentric Therapeutics, HTG Molecular Diagnostics, Institute of Molecular and Translational Medicine, Reveal Genomics, Roche Diagnostics International, Veru and ANGLE.

For a complete picture of the developmental pipeline for HER2 Amplification Tests devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.